Literature DB >> 24196625

[Molecular characterization of osteosarcomas].

D Baumhoer1.   

Abstract

Osteosarcomas are rare with an estimated incidence of 5-6 cases per one million inhabitants per year. As the prognosis has not improved significantly over the last 30 years and more than 30 % of patients still die of the disease a better understanding of the molecular tumorigenesis is urgently needed to identify prognostic and predictive biomarkers as well as potential therapeutic targets. Using genome-wide SNP chip analyses we were able to detect a genetic signature enabling a prognostic prediction of patients already at the time of initial diagnosis. Furthermore, we found the microRNA cluster 17-92 to be constitutively overexpressed in osteosarcomas. The microRNAs included here are intermingled in a complex network of several oncogenes and tumor suppressors that have been described to be deregulated in osteosarcomas. Therefore, the microRNA cluster 17-92 could represent a central regulator in the development of osteosarcomas.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24196625     DOI: 10.1007/s00292-013-1823-9

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  17 in total

Review 1.  Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database.

Authors:  Simona Ognjanovic; Magali Olivier; Tracy L Bergemann; Pierre Hainaut
Journal:  Cancer       Date:  2011-08-11       Impact factor: 6.860

2.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.

Authors:  Stefan S Bielack; Beate Kempf-Bielack; Günter Delling; G Ulrich Exner; Silke Flege; Knut Helmke; Rainer Kotz; Mechthild Salzer-Kuntschik; Matthias Werner; Winfried Winkelmann; Andreas Zoubek; Heribert Jürgens; Kurt Winkler
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

3.  Genomic alterations and allelic imbalances are strong prognostic predictors in osteosarcoma.

Authors:  Jan Smida; Daniel Baumhoer; Michael Rosemann; Axel Walch; Stefan Bielack; Christopher Poremba; Klaus Remberger; Eberhard Korsching; Wolfram Scheurlen; Christian Dierkes; Stefan Burdach; Gernot Jundt; Michael J Atkinson; Michaela Nathrath
Journal:  Clin Cancer Res       Date:  2010-07-07       Impact factor: 12.531

4.  MicroRNA profiling with correlation to gene expression revealed the oncogenic miR-17-92 cluster to be up-regulated in osteosarcoma.

Authors:  Daniel Baumhoer; Stephanie Zillmer; Kristian Unger; Michael Rosemann; Michael J Atkinson; Martin Irmler; Johannes Beckers; Heide Siggelkow; Irene von Luettichau; Gernot Jundt; Jan Smida; Michaela Nathrath
Journal:  Cancer Genet       Date:  2012-05

5.  A microRNA polycistron as a potential human oncogene.

Authors:  Lin He; J Michael Thomson; Michael T Hemann; Eva Hernando-Monge; David Mu; Summer Goodson; Scott Powers; Carlos Cordon-Cardo; Scott W Lowe; Gregory J Hannon; Scott M Hammond
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

6.  Feud or Friend? The Role of the miR-17-92 Cluster in Tumorigenesis.

Authors:  Jie Xiang; Ji Wu
Journal:  Curr Genomics       Date:  2010-04       Impact factor: 2.236

7.  MicroRNA-17-92 cluster regulates osteoblast proliferation and differentiation.

Authors:  Mingliang Zhou; Junrong Ma; Shiju Chen; Xiang Chen; Xijie Yu
Journal:  Endocrine       Date:  2013-05-15       Impact factor: 3.633

8.  Massive genomic rearrangement acquired in a single catastrophic event during cancer development.

Authors:  Philip J Stephens; Chris D Greenman; Beiyuan Fu; Fengtang Yang; Graham R Bignell; Laura J Mudie; Erin D Pleasance; King Wai Lau; David Beare; Lucy A Stebbings; Stuart McLaren; Meng-Lay Lin; David J McBride; Ignacio Varela; Serena Nik-Zainal; Catherine Leroy; Mingming Jia; Andrew Menzies; Adam P Butler; Jon W Teague; Michael A Quail; John Burton; Harold Swerdlow; Nigel P Carter; Laura A Morsberger; Christine Iacobuzio-Donahue; George A Follows; Anthony R Green; Adrienne M Flanagan; Michael R Stratton; P Andrew Futreal; Peter J Campbell
Journal:  Cell       Date:  2011-01-07       Impact factor: 41.582

9.  CRIP1 expression is correlated with a favorable outcome and less metastases in osteosarcoma patients.

Authors:  Daniel Baumhoer; Mareike Elsner; Jan Smida; Stephanie Zillmer; Sandra Rauser; Cédrik Schoene; Benjamin Balluff; Stefan Bielack; Gernot Jundt; Axel Walch; Michaela Nathrath
Journal:  Oncotarget       Date:  2011-12

10.  Second primary neoplasms in patients with retinoblastoma.

Authors:  G J Draper; B M Sanders; J E Kingston
Journal:  Br J Cancer       Date:  1986-05       Impact factor: 7.640

View more
  2 in total

1.  Does rarity mean imparity? Biological characteristics of osteosarcoma cells originating from the spine.

Authors:  Zhenhua Zhou; Yan Li; Xu Yan; Xudong Wang; Cheng Yang; Haifeng Wei; Xinghai Yang; Jianru Xiao
Journal:  J Cancer Res Clin Oncol       Date:  2017-05-27       Impact factor: 4.553

2.  SLC3A2 is upregulated in human osteosarcoma and promotes tumor growth through the PI3K/Akt signaling pathway.

Authors:  Bin Zhu; Dongdong Cheng; Lei Hou; Shumin Zhou; Tao Ying; Qingcheng Yang
Journal:  Oncol Rep       Date:  2017-03-27       Impact factor: 3.906

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.